OTCMKTS:DSNKY Daiichi Sankyo Q1 2027 Earnings Report $18.71 +0.43 (+2.35%) As of 03:12 PM Eastern ProfileEarnings HistoryForecast Daiichi Sankyo EPS ResultsActual EPS$0.24Consensus EPS $0.25Beat/MissMissed by -$0.01One Year Ago EPSN/ADaiichi Sankyo Revenue ResultsActual Revenue$3.61 billionExpected Revenue$3.32 billionBeat/MissBeat by +$291.86 millionYoY Revenue GrowthN/ADaiichi Sankyo Announcement DetailsQuarterQ1 2027Date7/31/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsDaiichi Sankyo's next earnings date is estimated for Friday, October 30, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Daiichi Sankyo Earnings HeadlinesDaiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up After Analyst UpgradeSeptember 24 at 5:32 AM | americanbankingnews.comAstra-Daiichi breast cancer drug Enhertu recommended for NHS use in EnglandSeptember 17, 2026 | msn.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.September 25 at 1:00 AM | InvestorPlace (Ad)New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular riskAugust 28, 2026 | businesswire.comDaiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization OrganizationAugust 24, 2026 | businesswire.comDaiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Lead New Commercialization Unit to Accelerate Growth of Innovative PortfolioAugust 24, 2026 | businesswire.comSee More Daiichi Sankyo Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Daiichi Sankyo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Daiichi Sankyo and other key companies, straight to your email. Email Address About Daiichi SankyoDaiichi Sankyo (OTCMKTS:DSNKY) Co., Ltd. is a Japan-based pharmaceutical company focused on the research, development, manufacture and commercialization of medicines. Its primary areas of activity include oncology, cardiovascular disease, and other specialty therapeutic fields, with an emphasis on innovative treatments and technologies. The company is particularly known for its antibody-drug conjugate (ADC) platform, which is designed to deliver potent cancer medicines directly to tumor cells. Daiichi Sankyo’s oncology portfolio includes Enhertu (trastuzumab deruxtecan), developed in collaboration with AstraZeneca, as well as other marketed and investigational ADC therapies. Its broader portfolio includes Lixiana, also known as Savaysa in some markets, an oral anticoagulant based on edoxaban. Daiichi Sankyo was formed in 2005 through the merger of Sankyo Co., Ltd. and Daiichi Pharmaceutical Co., Ltd., two established Japanese drugmakers. The company is headquartered in Tokyo and serves markets in Japan, North America, Europe and other international regions through its global research, manufacturing and commercial operations.View Daiichi Sankyo ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Space Stocks to Watch as SpaceX Reshapes the Launch MarketOil May Be Stronger Than It Looks—And Diamondback Is on SaleBlackBerry Shifts Gears With Coretura Deal Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
